ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) BEYOND LDLR TARGETING: FOCUS ON GLUCOSE METABOLISM

被引：0
|
作者：
Balzarotti, Gloria [1 ]
Tibolla, Gianpaolo [1 ]
Ruscica, Massimiliano [1 ]
Di Cairano, Eliana [1 ]
Perego, Carla [1 ]
Catapano, Alberico Luigi [1 ,3 ]
Norata, Giuseppe Danilo [1 ,2 ]
机构：
[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[2] Bassini Hosp, Sisa Ctr, Milan, Italy
[3] Irccs Multimed, Milan, Italy
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.332
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG204
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [31] The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus
    Fratczak, Aleksandra
    Polak, Karina
    Szczepanek, Michal
    Lis-Swiety, Anna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2022, 39 (04): : 645 - 650
  • [32] Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
    Abifadel, Marianne
    Rabes, Jean-Pierre
    Devillers, Martine
    Munnich, Arnold
    Erlich, Daniele
    Junien, Claudine
    Varret, Mathilde
    Boileau, Catherine
    HUMAN MUTATION, 2009, 30 (04) : 520 - 529
  • [33] Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
    Tombling, Benjamin J.
    Lammi, Carmen
    Bollati, Carlotta
    Anoldi, Anna
    Craik, David J.
    Wang, Conan K.
    CHEMBIOCHEM, 2021, 22 (12) : 2154 - 2160
  • [34] Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Wang, Yu
    Ye, Jiantao
    Li, Jie
    Chen, Cheng
    Huang, Junying
    Liu, Peiqing
    Huang, Heqing
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [35] Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Yu Wang
    Jiantao Ye
    Jie Li
    Cheng Chen
    Junying Huang
    Peiqing Liu
    Heqing Huang
    Cardiovascular Diabetology, 15
  • [36] Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
    Ferri, Nicola
    Tibolla, Gianpaolo
    Pirillo, Angela
    Cipollone, Francesco
    Mezzetti, Andrea
    Pacia, Stefano
    Corsini, Alberto
    Catapano, Alberico Luigi
    ATHEROSCLEROSIS, 2012, 220 (02) : 381 - 386
  • [37] Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
    Zhu, Yiming M.
    Anderson, Todd J.
    Sikdar, Khokan
    Fung, Marinda
    McQueen, Matthew J.
    Lonn, Eva M.
    Verma, Subodh
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (10) : 2254 - 2259
  • [38] Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
    Metkus, Thomas S.
    Kim, Bo Soo
    Jones, Steven R.
    Martin, Seth S.
    Schulman, Steven P.
    Leucker, Thorsten M.
    FRONTIERS IN MEDICINE, 2022, 9
  • [39] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) LEVEL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN RUSSIA
    Benimetskaya, Kseniya
    Ragino, Yulia
    Shakhtshneider, Elena
    Makarenkova, Kseniya
    Stakhneva, Ekaterina
    Astrakov, Sergey
    Shchepina, Yulia
    Voevoda, Mikhail
    ATHEROSCLEROSIS, 2017, 263 : E195 - E195
  • [40] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
12345